Attention:
Dengue Crisis in the
Americas Region!
According to PAHO*, Costa Rica, Guatemala, French Guiana, Guadeloupe, Martinique, Paraguay, and Peru have reported increases in dengue outbreaks between EW 1 and EW 5 of 2024.
*Pan American Health Organization • www.paho.org. Epidemiological Alert Report - February 16, 2024
VIDAS® ARBOVIRUSES PANEL
New Arboviruses assays VIDAS® DENGUE NS1, IgM, IgG and VIDAS® CHIKUNGUNYA IgM and IgG complete our VIDAS® ID Menu. With them, VIDAS® is reloaded to last.
During 2023, 23 countries and territories recorded dengue outbreaks exceeding expectations: Belize, Bolivia, Costa Rica, Ecuador, Guatemala, Honduras, Saint Martin, Jamaica, Martinique, Nicaragua, Panama, Paraguay, the Dominican Republic, Saint Barthélemy, and Suriname.
The situation of high transmission continued into 2024, where from epidemiological week (EW) 1 to EW 5, 673,267 dengue cases were reported, of which 700 were severe (0.1%) and 102 cases were fatal (fatality rate 0.015%). This figure represents a 157% increase compared to the same period in 2023 and 225% compared to the average of the last 5 years.
Specific data for each country on case counts and completeness can be found at
VIDAS® DENGUE PANEL
BECAUSE IT MAKES SENSE ON VIDAS®
Reliable & clear-cut results
Automated result interpretation
Accessible to all laboratories
A COMPLETE SOLUTION FOR DENGUE DIAGNOSIS
WITH 3 INDEPENDENT & COMPLEMENTARY TESTS:
NS1
The NS1 antigen is an early and sensitive viral marker of acute infection. It is the ideal solution for laboratories without access to RT-PCR, to detect the virus.
IgM
If IgM appears earlier than IgG, it also disappears earlier. This makes IgM an early marker of acute primary infection.
IgG
IgG is used to determine the presence of specific immunity.
Chronology of the humoral response and biomarker emergence during primary and secondary dengue infection.
VIDAS® CHIKUNGUNYA PANEL
2 complementary tests
The VIDAS® CHIKUNGUNYA panel offers 2 complementary tests for accurate detection of the disease from the acute to the chronic phase:
VIDAS® Anti-CHIKUNGUNYA IgM: Early serological response
VIDAS® Anti-CHIKUNGUNYA IgG: Presence of specific immunity
Reliable and clear-cut results
VIDAS® Anti-CHIKUNGUNYA IgM
Immunocapture allows excellent performance
VIDAS® Anti- CHIKUNGUNYA IgG
No cross reactivity with dengue, Zika, yellow fever and SARS-COV-2
Recommended Diagnostic Methods
(1)
3 specific chikungunya biomarkers are expressed after infection:
The presence of virus in the blood (viremia) can be detected early in the course of infection, and up to 7-10 days after the first symptoms.
Anti-CHIKUNGUNYA IgM antibodies are generally detectable 5-7 days after the contamination. It is classically admitted that they persist for several weeks, up to 3 months. However, it has been demonstrated that they can be detected in the blood of infected people up to more than one year after the acute phase.
Anti-CHIKUNGUNYA IgG antibodies are detectable a few days after IgM appearance, 7-10 days after the contamination, and can persist for years.
VIDAS® Anti-CHIKUNGUNYA IgM and IgG KINETICS
